(PRWEB) January 20, 2015
ClinicoEconomics and Outcomes Research has published the original research “Value analysis of digital breast tomosynthesis for breast cancer screening in a commercially-insured US population”.
“There are over 39 million mammograms each year in the U.S.,” said Machaon Bonafede, PhD, MPH, outcomes research director and lead author of the study at Truven Health Analytics. “With approximately one in seven women receiving additional diagnostic imaging following 2D digital screening mammography, the adoption of breast tomosynthesis presents an opportunity for delivering value-based care by potentially reducing costs to payers and reducing patient burden associated with unnecessary follow-up care.”
Co-author Jeffrey Miller, MS, director of economic modeling at Truven Health added, “To our knowledge, this is the first paper published on this topic and it is particularly timely as breast tomosynthesis screening becomes mainstream. The economic findings from our analyses suggest that breast tomosynthesis is producing positive outcomes for both cost and quality.”
As Professor Giorgio Colombo, Editor-in-Chief, explains “Breast cancer is the most common cancer among women, accounting for 29% of newly diagnosed cancers, and is the second most common cause of death from cancer in women in the US. The objective of this study was to conduct a value analysis of digital breast tomosynthesis (DBT) for breast cancer screening among women enrolled in US commercial health insurance plans to assess its clinical benefits, associated expenditures, and net budget impact. Use of DBT as a mammography screening modality substantially reduces the need for follow-up diagnostic services and improves detection of invasive cancers, allowing for earlier, less-costly treatment. Results from our value analysis of DBT demonstrate that these beneficial attributes could translate into meaningful cost savings for US commercial health insurers. Investigation of longer term outcomes is also warranted to better understand the broader clinical and economic implications of DBT adoption.”
ClinicoEconomics and Outcomes Research is an international, peer-reviewed open-access journal focusing on Health Technology Assessment, Pharmacoeconomics and Outcomes Research in the areas of diagnosis, medical devices, and clinical, surgical and pharmacological intervention. The economic impact of health policy and health systems organization also constitute important areas of coverage.
Dove Medical Press Ltd is a privately held company specializing in the publication of Open Access peer-reviewed journals across the broad spectrum of science, technology and especially medicine.